» Articles » PMID: 36797236

Signaling Pathways in Rheumatoid Arthritis: Implications for Targeted Therapy

Overview
Date 2023 Feb 16
PMID 36797236
Authors
Affiliations
Soon will be listed here.
Abstract

Rheumatoid arthritis (RA) is an incurable systemic autoimmune disease. Disease progression leads to joint deformity and associated loss of function, which significantly impacts the quality of life for sufferers and adds to losses in the labor force. In the past few decades, RA has attracted increased attention from researchers, the abnormal signaling pathways in RA are a very important research field in the diagnosis and treatment of RA, which provides important evidence for understanding this complex disease and developing novel RA-linked intervention targets. The current review intends to provide a comprehensive overview of RA, including a general introduction to the disease, historical events, epidemiology, risk factors, and pathological process, highlight the primary research progress of the disease and various signaling pathways and molecular mechanisms, including genetic factors, epigenetic factors, summarize the most recent developments in identifying novel signaling pathways in RA and new inhibitors for treating RA. therapeutic interventions including approved drugs, clinical drugs, pre-clinical drugs, and cutting-edge therapeutic technologies. These developments will hopefully drive progress in new strategically targeted therapies and hope to provide novel ideas for RA treatment options in the future.

Citing Articles

CUR-PDT induces ferroptosis of RA-FLS via the Nrf2/xCT/GPX4 pathway to inhibit proliferation in rheumatoid arthritis.

Sun L, Niu Y, Liao B, Liu L, Peng Y, Li K Inflamm Res. 2025; 74(1):53.

PMID: 40085199 DOI: 10.1007/s00011-025-02019-2.


Identification biomarkers and therapeutic targets of disulfidptosis-related in rheumatoid arthritis via bioinformatics, molecular dynamics simulation, and experimental validation.

Xu B, Zhang H, Shen B, Wu J, Shi M, Li X Sci Rep. 2025; 15(1):8779.

PMID: 40082645 PMC: 11906621. DOI: 10.1038/s41598-025-93656-4.


There and turn back again: the application of phage serine integrases in eukaryotic systems.

Sales T, de Oliveira M, Florentino L, Lima R, Rech E Front Bioeng Biotechnol. 2025; 13:1478413.

PMID: 40066361 PMC: 11891168. DOI: 10.3389/fbioe.2025.1478413.


Anti-arthritic potential of linalool: in vitro, in vivo, and in silico mechanistic insights for safer therapeutic applications.

Ahammed S, Chowdhury R, Al Hasan M, Mia E, Akbor M, Islam M Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 40055204 DOI: 10.1007/s00210-025-03984-5.


The double-edged sword of lncRNAs in rheumatoid arthritis: from controlling the disease to its progress.

Liu Z, Xu H, Chen Z Clin Exp Med. 2025; 25(1):76.

PMID: 40053152 PMC: 11889058. DOI: 10.1007/s10238-025-01567-5.


References
1.
Auger I, Roudier J . HLA-DR and the development of rheumatoid arthritis. Autoimmunity. 1997; 26(2):123-8. DOI: 10.3109/08916939709003856. View

2.
Owens B, Steevels T, Dudek M, Walcott D, Sun M, Mayer A . CD90(+) Stromal Cells are Non-Professional Innate Immune Effectors of the Human Colonic Mucosa. Front Immunol. 2013; 4:307. PMC: 3786311. DOI: 10.3389/fimmu.2013.00307. View

3.
Rabelo F, Mota L, Lima R, Lima F, Barra G, de Carvalho J . The Wnt signaling pathway and rheumatoid arthritis. Autoimmun Rev. 2009; 9(4):207-10. DOI: 10.1016/j.autrev.2009.08.003. View

4.
Mota L, Laurindo I, Dos Santos Neto L, Lima F, Viana S, Mendlovitz P . Imaging diagnosis of early rheumatoid arthritis. Rev Bras Reumatol. 2012; 52(5):757-66. View

5.
Shavlovskaya O, Bokova I, Shavlovskiy N . [Meloxicam clinical effects]. Zh Nevrol Psikhiatr Im S S Korsakova. 2022; 122(1):36-42. DOI: 10.17116/jnevro202212201136. View